These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28348561)

  • 1. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients.
    Saavedra D; Crombet T
    Front Immunol; 2017; 8():269. PubMed ID: 28348561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
    Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
    Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
    Saavedra D; Neninger E; Rodriguez C; Viada C; Mazorra Z; Lage A; Crombet T
    Semin Oncol; 2018 Jan; 45(1-2):34-40. PubMed ID: 30318082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy.
    Rodríguez PC; Rodríguez G; González G; Lage A
    MEDICC Rev; 2010; 12(1):17-23. PubMed ID: 20387330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
    Ortiz Carrodeguas RA; Lorenzo Monteagudo G; Guerra Chaviano PP; Álvarez Montané I; Salomón Saldívar EE; Lobaina Lambert L; Camacho Sosa K; Bermúdez Pino R; Blanco Mustelier P; Valdés Rodríguez E; González Piloto S; Guerra de la Vega A; Valdés Sánchez L; Montes De Santis A; Parra Zabala J; Viada González C; Calvo Aguilera N; Saavedra Hernández D; Santos Morales O; Crombet Ramos T
    Front Oncol; 2023; 13():1287902. PubMed ID: 38304035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
    Tagliamento M; Rijavec E; Barletta G; Biello F; Rossi G; Grossi F; Genova C
    Expert Opin Biol Ther; 2018 Jul; 18(7):829-835. PubMed ID: 29936901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.
    Crombet Ramos T; Rodríguez PC; Neninger Vinageras E; Garcia Verdecia B; Lage Davila A
    Expert Rev Vaccines; 2015; 14(10):1303-11. PubMed ID: 26295963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.
    Flores Vega YI; Páramo González DL; Alsina Sarmiento SC; Alsina Tul LE; Inguanzo Valdés IB; Rodríguez Machado J; Elejalde Larrinaga Á; Flores Rodríguez JE; Lamadrid García J; Corrales Otero D; Ropero Toirac R; Crombet Ramos T; Gracia Medina EA
    J Cancer; 2023; 14(5):874-879. PubMed ID: 37056397
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
    Popa X; García B; Fuentes KP; Huerta V; Alvarez K; Viada CE; Neninger E; Rodríguez PC; González Z; González A; Crombet T; Mazorra Z
    Oncoimmunology; 2020 May; 9(1):1762465. PubMed ID: 32923124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
    Evans R; Lee K; Wallace PK; Reid M; Muhitch J; Dozier A; Mesa C; Luaces PL; Santos-Morales O; Groman A; Cedeno C; Cinquino A; Fisher DT; Puzanov I; Opyrchal M; Fountzilas C; Dai T; Ernstoff M; Attwood K; Hutson A; Johnson C; Mazorra Z; Saavedra D; Leon K; Lage A; Crombet T; Dy GK
    Front Oncol; 2022; 12():958043. PubMed ID: 35992783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.
    Crombet Ramos T; Santos Morales O; Dy GK; León Monzón K; Lage Dávila A
    Front Oncol; 2021; 11():639745. PubMed ID: 34211836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity.
    Mancebo A; Casacó A; González B; Ledón N; Sorlozabal J; León A; Gómez D; González Y; Bada AM; González C; Arteaga ME; Ramírez H; Fuentes D
    Vaccine; 2012 May; 30(22):3329-38. PubMed ID: 22433960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
    Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
    BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
    Zhang JY; Zhu L; Yang HK; Chen F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
    Suárez GM; Catalá M; Peña Y; Portela S; Añé-Kourí AL; González A; Lorenzo-Luaces P; Díaz M; Molina MLA; Pereira K; Hernández JC; Ramos R; Reyes MC; Ledón N; Mazorra Z; Crombet T; Lage A; Saavedra D
    Front Oncol; 2022; 12():823287. PubMed ID: 35155258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
    Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
    J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.
    Fernández Lorente A; Acosta Brooks S; Neninger Vinageras E; Barroso Alvarez Mdel C; Wilkinson Brito B; Troche Concepción M; Martínez Pérez LB; Viada González CE; Crespo Diaz T; Casacó Parada AR
    World J Surg Oncol; 2013 Oct; 11():275. PubMed ID: 24127898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.
    Saavedra D; García B; Lorenzo-Luaces P; González A; Popa X; Fuentes KP; Mazorra Z; Crombet T; Neninger E; Lage A
    Cancer Immunol Immunother; 2016 Jan; 65(1):37-45. PubMed ID: 26589409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
    García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
    Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.